Rapamycin Holdings

Rapamycin Holdings
Rapamycin Holdings, Inc. licenses rapamycin-related intellectual property developed at the UTHSCSA. Rapamycin, a drug federally approved to suppress organ rejection, continues to be studied for its potential to slow the aging process and its efficacy in treating age-related diseases. The Horizon Fund is investing in Rapamycin Holdings under the Existing Ventures funding program.

Partners